Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab + PD-1 Inhibitor + Chemo in NSCLC
NCT07034391Phase 2Recruiting
- Sponsor
- China Medical University
- Start
- May 2025
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of denosumab in non-small cell lung cancer (NSCLC), sponsored by China Medical University. Started May 2025; status: recruiting.
02
Drugs
denosumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07034391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07034391.